Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
KZIA
KZIA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
KZIA News
Challenges and Opportunities in Neuro-Oncology
Jun 03 2026
Newsfilter
Kazia Therapeutics Appoints New CFO James Levine
Jun 02 2026
PRnewswire
Kazia Therapeutics Appoints New CFO to Drive Financial Strategy
Jun 02 2026
Newsfilter
Kazia Plans to Increase Patient Enrollment in Clinical Trial
May 26 2026
PRnewswire
Kazia Appoints New Chief Scientific Officer
Apr 15 2026
PRnewswire
Kazia Acquires SETDB1-Targeted Drug Development Platform
Apr 13 2026
PRnewswire
Kazia Acquires SETDB1-targeted Drug Development Platform
Apr 13 2026
Newsfilter
Kazia's NDL2 Therapy Significantly Reduces Tumor Volume
Jan 30 2026
stocktwits
Kazia Launches First-in-Class Nuclear PD-L1 Degrader NDL2
Jan 30 2026
PRnewswire
Kazia Therapeutics Provides Clinical Update on Paxalisib in TNBC Study
Jan 27 2026
Benzinga
Kazia Therapeutics Updates on Clinical Trial Progress
Jan 27 2026
PRnewswire
Kazia CEO John Friend to Attend JPM Week, Advancing Breast Cancer Research
Jan 08 2026
Newsfilter
Oncolytics Biotech Inc. Reports 33% Response Rate for Pelareorep in Colorectal Cancer
Jan 07 2026
Newsfilter
Oncolytics Biotech's Immunotherapy Shows Significant Improvement in Cancer Treatment Outcomes
Jan 07 2026
PRnewswire
GH Research PLC Shares Surge 18.1% on FDA IND Status Update Announcement
Jan 05 2026
Benzinga
Kazia Regains Nasdaq Compliance Following $50 Million Institutional Financing
Dec 22 2025
PRnewswire
Show More News
